DETAILED NOTES ON HEMGENIX

Quantity of eligible individuals: CDEC talked about the uncertainty in the quantity of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who will be labeled as possessing gentle or moderate condition could have a signifi